(BMEZ) BlackRock Health Sciences - Ratings and Ratios
Biotech, Pharmaceuticals, Medical Devices, Healthcare Services
BMEZ EPS (Earnings per Share)
BMEZ Revenue
Description: BMEZ BlackRock Health Sciences
BlackRock Health Sciences Trust II (BMEZ) is a closed-end investment fund that focuses on the healthcare sector, specifically on healthcare services. As a common stock listed on the NYSE, its performance is influenced by the overall healthcare industry trends and economic conditions.
The funds investment strategy is centered around the healthcare services sub-industry, which includes companies providing healthcare services, such as hospitals, healthcare facilities, and medical services providers. The demand for healthcare services is driven by demographic factors, such as an aging population, and economic factors, such as GDP growth and government healthcare spending.
Key performance indicators (KPIs) to monitor for BMEZ include its net asset value (NAV) growth, dividend yield, and the overall performance of its underlying portfolio. The funds NAV is influenced by the market value of its holdings, which are primarily composed of healthcare services companies. A rising NAV indicates a positive performance of the funds investments.
Economic drivers that impact BMEZs performance include government policies and regulations affecting the healthcare industry, technological advancements in healthcare, and demographic changes. For instance, an increase in government spending on healthcare programs or a rise in the prevalence of chronic diseases can positively impact the demand for healthcare services, thereby benefiting the fund.
To evaluate BMEZs investment potential, one should examine its market capitalization, price-to-earnings (P/E) ratio, and dividend yield in comparison to its peers and the broader healthcare sector. A high P/E ratio, such as 67.43, may indicate that the fund is trading at a premium to its earnings, potentially making it less attractive to income-focused investors.
From a trading perspective, monitoring BMEZs price movements, trading volume, and volatility can provide insights into market sentiment and potential trading opportunities. The funds average trading volume and ATR (average true range) can help investors gauge liquidity and potential price swings.
BMEZ Stock Overview
| Market Cap in USD | 889m |
| Sub-Industry | Health Care Services |
| IPO / Inception | 2020-01-29 |
BMEZ Stock Ratings
| Growth Rating | 13.8% |
| Fundamental | 66.5% |
| Dividend Rating | 91.1% |
| Return 12m vs S&P 500 | -13.6% |
| Analyst Rating | - |
BMEZ Dividends
| Dividend Yield 12m | 14.77% |
| Yield on Cost 5y | 14.19% |
| Annual Growth 5y | 13.44% |
| Payout Consistency | 97.7% |
| Payout Ratio | 846.8% |
BMEZ Growth Ratios
| Growth Correlation 3m | 45.3% |
| Growth Correlation 12m | 11.1% |
| Growth Correlation 5y | -32.8% |
| CAGR 5y | 7.52% |
| CAGR/Max DD 3y | 0.41 |
| CAGR/Mean DD 3y | 1.79 |
| Sharpe Ratio 12m | 0.63 |
| Alpha | -17.50 |
| Beta | 0.925 |
| Volatility | 12.81% |
| Current Volume | 386.8k |
| Average Volume 20d | 192.6k |
| Stop Loss | 13.8 (-3%) |
| Signal | -0.84 |
Piotroski VR‑10 (Strict, 0-10) 5.0
| Net Income (43.5m TTM) > 0 and > 6% of Revenue (6% = 4.27m TTM) |
| FCFTA 0.08 (>2.0%) and ΔFCFTA 3.18pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.00 (>3.0%) and CFO -970.2k <= Net Income 43.5m (YES >=105%, WARN >=100%) |
| Net Debt (-71.3k) to EBITDA (43.5m) ratio: -0.00 <= 3.0 (WARN <= 3.5) |
| Current Ratio 21.52 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (13.3m) change vs 12m ago NaN% (target <= -2.0% for YES) |
| Gross Margin 82.62% (prev 0.0%; Δ 82.62pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 10.32% (prev 3.37%; Δ 6.95pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 100.0k (EBITDA TTM 43.5m / Interest Expense TTM 78.0) >= 6 (WARN >= 3) |
ValueRay F-Score (Strict, 0-100) 66.52
| 1. Piotroski 5.0pt = 0.0 |
| 2. FCF Yield 7.59% = 3.80 |
| 3. FCF Margin 91.99% = 7.50 |
| 4. Debt/Equity data missing |
| 5. Debt/Ebitda data missing |
| 6. ROIC - WACC 4.63% = 5.79 |
| 7. RoE 6.77% = 0.56 |
| 8. Rev. Trend -9.74% = -0.49 |
| 9. Rev. CAGR 0.0% = 0.0 |
| 10. EPS Trend -25.60% = -0.64 |
| 11. EPS CAGR 0.0% = 0.0 |
What is the price of BMEZ shares?
Over the past week, the price has changed by -2.27%, over one month by +1.03%, over three months by +0.88% and over the past year by +2.15%.
Is BlackRock Health Sciences a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BMEZ is around 14.52 USD . This means that BMEZ is currently overvalued and has a potential downside of 2.04%.
Is BMEZ a buy, sell or hold?
What are the forecasts/targets for the BMEZ price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 16.3 | 14.7% |
Last update: 2025-09-15 02:04
BMEZ Fundamental Data Overview
CCE Cash And Equivalents = 26.6m USD (Cash And Short Term Investments, last quarter)
P/S = 23.3725
P/B = 0.9284
Beta = None
Revenue TTM = 71.2m USD
EBIT TTM = 43.5m USD
EBITDA TTM = 43.5m USD
Long Term Debt = unknown (none)
Short Term Debt = 1.23m USD (from totalCurrentLiabilities, two quarters ago)
Debt = unknown
Net Debt = -71.3k USD (from netDebt column, last quarter)
Enterprise Value = 862.8m USD (889.4m + (null Debt) - CCE 26.6m)
Interest Coverage Ratio = 557.3k (Ebit TTM 43.5m / Interest Expense TTM 78.0)
FCF Yield = 7.59% (FCF TTM 65.5m / Enterprise Value 862.8m)
FCF Margin = 91.99% (FCF TTM 65.5m / Revenue TTM 71.2m)
Net Margin = 61.04% (Net Income TTM 43.5m / Revenue TTM 71.2m)
Gross Margin = 82.62% ((Revenue TTM 71.2m - Cost of Revenue TTM 12.4m) / Revenue TTM)
Tobins Q-Ratio = 1.12 (Enterprise Value 862.8m / Book Value Of Equity 768.6m)
Interest Expense / Debt = unknown (Interest Expense 78.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 34.3m (EBIT 43.5m * (1 - 21.00%))
Current Ratio = 21.52 (Total Current Assets 26.6m / Total Current Liabilities 1.23m)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt -71.3k / EBITDA 43.5m)
Debt / FCF = none (Debt none / FCF TTM 65.5m)
Total Stockholder Equity = 642.6m (last 4 quarters mean)
RoA = 5.61% (Net Income 43.5m, Total Assets 774.6m )
RoE = 6.77% (Net Income TTM 43.5m / Total Stockholder Equity 642.6m)
RoCE = unknown (Ebit 43.5m / (Equity 642.6m + L.T.Debt none))
RoIC = 4.63% (NOPAT 34.3m / Invested Capital 742.0m)
WACC = unknown (E(889.4m)/V(0.0) * Re(9.42%)) + (D(none)/V(0.0) * Rd(none%) * (1-Tc(0.21)))
Shares Correlation 3-Years: -82.38 | Cagr: -22.38%
Discount Rate = 9.42% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 77.10% ; FCFE base≈52.1m ; Y1≈64.3m ; Y5≈109.7m
Fair Price DCF = 23.29 (DCF Value 1.46b / Shares Outstanding 62.5m; 5y FCF grow 25.0% → 3.0% )
Revenue Correlation: -9.74 | Revenue CAGR: 0.0%
Rev Growth-of-Growth: N/A
EPS Correlation: -25.60 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 143.1
Additional Sources for BMEZ Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle